ReNeuron Group plc Total Voting Rights (5278N)

TIDMRENE

RNS Number : 5278N

ReNeuron Group plc

01 February 2021

 
 1 February 2021   AIM: RENE 
 

ReNeuron Group plc

("ReNeuron" or the "Company")

Total Voting Rights

At 31 January 2021, the Company had 56,855,705 ordinary shares in issue, each carrying one voting right. This follows the issue of 9,000 new shares arising from the exercise of options by staff, such shares having been admitted under the Company's existing block listing arrangement.

As the Company holds no ordinary shares in treasury, the figure of 56,855,705 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

ENDS

ENQUIRIES:

 
ReNeuron                                                  [phone] 
Olav Hellebø, Chief Executive Officer 
Michael Hunt, Chief Financial Officer 
 [e-mail] 
Buchanan (Media/Investor relations)                       [phone] 
Mark Court, Sophie Wills, Tilly Abraham 
 [e-mail] 
Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)   [phone] 
Stewart Wallace, Ben Maddison 
 (NOMAD and Joint Broker) 
N+1 Singer (Joint Broker)                                 [phone] 
Aubrey Powell, James Moat, Tom Salvesen 
 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke.

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRKZGGZLMFGMZG

(END) Dow Jones Newswires

February 01, 2021 04:55 ET (09:55 GMT)